Referent:in
Erasmus Medical Center, Netherlands
Pulmonary physician at the Erasmus University Medical Centre in Rotterdam, a national expert centre for interstitial lung diseases (ILD) in the Netherlands and member of the European Reference Network for Rare Lung Diseases (ERN-Lung).
Referent:in
LUMC (Leiden University Medical Center), Department of Rheumatology, C1-R, The Netherlands
rheumatologist; MD, PhD - Head Leiden SSc/ CTD care pathway; PI Leiden CCISS cohort
Let‘s change lives.
In 1921, Boehringer Ingelheim set out with a vision to transform the world of respiratory care. Now, in 2024 the company looks back on more than 100 years of pushing the boundaries in scientific innovation and research to create groundbreaking solutions across a range of respiratory conditions. Over the past century, Boehringer Ingelheim has emerged as a leader in this therapy area, having launched several treatments in a range of respiratory conditions including chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis. The focus has always been to improve the quality of life for patients suffering from debilitating respiratory diseases and enable them to maintain a more independent lifestyle.